Over a month ago |
Earnings
|
Reports Q4 revenue $22M,… Reports Q4 revenue $22M, consensus $22.13M. ShowHide Related Items >><< - 02/23/23
- Nektar down 31% afterhours after update on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading resumes
- 02/23/23
- Nektar reports Phase 2 data on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading halted, news pending
- 02/24/23 SVB Securities
- Nektar price target lowered to $3 from $5 at SVB Securities
- 02/24/23 Jefferies
- Nektar downgraded to Underperform from Hold at Jefferies
- 11/29/22 Guggenheim
- Guggenheim starts Medicenna Therapeutics with a Buy on MDNA11 potential
- 08/08/22 JPMorgan
- Nektar downgraded to Underweight from Neutral at JPMorgan
- 11/03/22
- Nektar reports Q3 EPS (31c), consensus (45c)
- 02/24/23
- What You Missed On Wall Street On Friday
- 02/24/23
- What You Missed On Wall Street This Morning
- 02/24/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/23/23
- Fly Intel: After-Hours Movers
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 02/24/23
- Zeta Global rises 12.4%
- 02/24/23
- Zeta Global rises 12.0%
- 11/30/22
- Zeta Global announces record results for ZMP
- 02/23/23
- Yeti falls 9% to $36.02 after Q4 results, FY23 guidance miss estimates
- 02/16/23
- Yeti appoints Mike McMullen as CFO
- 02/06/23
- Yeti identifies a 'potential safety concern' regarding certain products
- 01/24/23
- YETI Holdings trading resumes
WBD Warner Bros. Discovery - 02/23/23
- Warner Bros. says 'Hogwarts Legacy' sells over 12M units in first two weeks
- 02/23/23
- Warner Bros. Discovery reports Q4 cash provided by operating activities $2.85B
- 02/23/23
- Warner Bros. Discovery reports 96.1M global DTC subscribers at end of Q4
- 02/12/23
- Fly Intel: Top five weekend stock stories
- $24.01 /
+2.425 (+11.24%) - 02/23/23
- Turning Point Brands raises quarterly dividend 8% to 6.5c per share
- 10/26/22
- Turning Point Brands sees FY22 adjusted EBITDA $96M-$99M
- 10/17/22
- Turning Point Brands sees FY22 adjusted EBITDA $96M-$99M
- 10/17/22
- Turning Point Brands CEO Yavor Efremov resigns, Graham Purdy succeeds
- 01/19/23
- Complexity Gaming renews partnership with Miller Lite
- 10/06/22
- Molson Coors announces new partnership with the Professional Pickleball Assoc
- 09/29/22
- Molson Coors expands agreement with Coca-Cola to develop Topo Chico Spirited
- 02/23/23
- Block sees FY23 adjusted EBITEA at $1.3B vs. $991M in FY22
- 02/23/23
- Block sees combined company gross profit in January-February up 25%
- 02/23/23
- Block reports Q4 cash app gross profit $848M vs. $518M last year
- 02/23/23
- Block reports Q4 gross payment volume $48.6B vs. $42.6B last year
- $28.25 /
+3.005 (+11.90%) - 02/24/23
- Range Resources extends rally, shares up 15% to $29.01
- 02/24/23
- Range Resources trading resumes
- 02/24/23
- Range Resources higher, Pioneer Natural lower after report on possible tie-up
- 02/24/23
- Range Resources jumps 12% to $28.31 after report of Pioneer Natural interest
- 02/22/23
- Pioneer Natural sees FY23 Capital Budget $4.45B-$4.75B
- 02/22/23
- Pioneer Natural sees Q1 oil production 349-364 MBOPD
NVTS Navitas Semiconductor - 02/13/23
- Navitas Semiconductor announces GaNFast tech in OnePlus 11 5G smartphone
- 02/01/23
- Navitas Semiconductor welcomes visitors to 'Planet Navitas'
- 01/19/23
- Navitas acquires silicon control IC from JV from Halo for price of $20M in stock
- 12/28/22
- 'Navitas Presents:' Partner Insights at CES 2024
- 02/23/23
- Nektar down 31% afterhours after update on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading resumes
- 02/23/23
- Nektar reports Phase 2 data on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading halted, news pending
- $139.27 /
-8.365 (-5.67%) - 02/23/23
- Moderna says $2.8B remaining under latest buyback authorization
- 02/23/23
- Moderna backs forecast of $5B in COVID-19 sales contracted for 2023 delivery
- 02/23/23
- Moderna sees FY23 CapEx at about $1.0B and R&D expense at about $4.5B
- 02/23/23
- Moderna, Merck granted FDA Breakthrough Therapy Designation for mRNA-4157/V940
- 01/30/23
- MoneyGram provides update on acquisition by MDP
- 01/25/23
- MoneyGram announces strategic partnership with Astra Tech
- 12/21/22
- MoneyGram merger with Madison Dearborn receives penultimate regulatory approval
- 11/14/22
- MoneyGram announces partnership with Beyon Money
- $12.98 /
+1.505 (+13.12%) - 02/23/23
- Kratos Defense receives $49.57M Navy FRP contract
- 02/23/23
- Kratos Defense sees total FY23 CapEx $45M-$50M
- 02/22/23
- Kratos Defense releases OpenEdge products
- 01/10/23
- Kratos Defense receives Mayhem hypersonic missile program contract award
- 02/24/23
- Goldman Sachs announces new buyback program up to $30B of shares
- 02/06/23
- Carlyle Group names Harvey Schwartz as CEO, board member
- 02/02/23
- Carlyle in talks with ex-Goldman exec Schwartz for CEO role, Semafor says
- 01/20/23
- Goldman Sachs down 2% after WSJ report on Fed probe of Marcus unit
FULC Fulcrum Therapeutics - 02/24/23
- Fulcrum Therapeutics announces clinical hold on FTX-6058 in SCD
- 01/24/23
- Fulcrum Therapeutics jumps 7% as Ra Capital discloses $25M purchase
- 01/04/23
- Fulcrum Therapeutics sees cash runway into late 2024
- 01/04/23
- Fulcrum Therapeutics provides business update, upcoming milestones
- 02/24/23
- Farfetch rises 13.0%
- 02/23/23
- Farfetch CFO Jordan to step down by end of 2023
- 01/18/23
- Farfetch announces changes to leadership team
- 12/29/22
- Farfetch rises 11.7%
- 01/11/23
- RFK Racing enters team-wide partnership with Esperion
- 12/07/22
- Esperion announces CLEAR cardiovascular outcomes trial of NEXLETOL
- 11/16/22
- Esperion promotes Ben Halladay to CFO role
- 08/26/22
- Esperion: NEXLETOL recommended as oral non-statin therapy by ACC task force
- 01/12/23
- Ericsson makes $220M provision in Q4 for potential DPA breach resolution
- 01/11/23
- Ericsson Nomination Committee proposes board, Jan Carlson as chairman
- 01/10/23
- Intel unveils 4th Gen Xeon Scalable processors, Xeon CPU Max Series
- 12/15/22
- Ericsson provides long-term targets and strategy on 2022 Capital Markets Day
- $297.42 /
-10.58 (-3.44%) - 02/23/23
- Domino's Pizza falls -10.2%
- 02/23/23
- Domino's Pizza sees FY23 CapEx $90M-$100M
- 02/23/23
- Domino's Pizza cuts two-to three-year outlook for global retail sales growth
- 12/15/22
- Domino's Pizza to enter Uruguay and Latvia
- $12.21 /
-1.555 (-11.30%) - 09/21/22
- DigitalBridge CEO buys $487K in common stock
- 09/14/22
- DigitalBridge reinstates dividend with 1c per share
- 02/24/23
- Cvent down 3% to $7.40 after Reuters report of rejected Blackstone bid
- 01/31/23
- Cvent jumps 15% after WSJ says company exploring sale
- 11/09/22
- Cvent, Zoom Video partner for hybrid events
- 10/19/22
- American Express, Cvent team up on virtual payment capabilities
- 02/24/23
- Cinemark falls 5% to $12.36 after Q4 results miss estimates
- 02/15/23
- Cinemark founder Lee Roy Mitchell to retire from board
- 01/24/23
- Cinemark and EntTelligence extend service agreement
- 11/23/22
- Film exhibitor stocks higher after report of Amazon spending plans
- $18.86 /
+1.725 (+10.07%) - 02/23/23
- Beyond Meat 'encouraged' by 14% improvement in margin expansion
- 02/23/23
- Beyond Meat up 15% after reporting Q4 earnings results
- 01/03/23
- Beyond Meat says 'Beyond Steak' now available at select Costco locations
- 12/29/22
- Beyond Meat rises after McDonald's UK&I announces 'Double McPlant'
- 02/14/23
- Tiger Global boosts stakes in Visa, Mastercard, reduces position in Microsoft
- 02/10/23
- Altus Power, CBRE and Blackstone advance Community Solar Partnership Program
- 02/01/23
- Blackstone says BREIT repurchase requests exceeded monthly limit in January
- $2,455.00 /
+25.9 (+1.07%) - 02/23/23
- Booking announces $20B share repurchase authorization
- 02/23/23
- Booking Holdings CEO says 'proud of our company's performance' in 2022
- 02/14/23
- Lone Pine exited PayPal, initiated AMD position during Q4
- 02/13/23
- Soros Fund buys Horizon Therapeutics, exits BNY Mellon in Q4
- $198.10 /
-10.045 (-4.83%) - 02/23/23
- American Airlines chairman Doug Parker to retire, Greg Smith to succeed
- 02/23/23
- Boeing drops 2% to $204 after WSJ report of halted Dreamliner deliveries
- 02/23/23
- Boeing sees completing new-build production of F/A-18 Super Hornet in late 2025
- 02/15/23
- Boeing sees clearing 100 Dreamliners from storage by end of 2024, says CFO
- $320.50 /
-26.42 (-7.62%) - 02/15/23
- European Commission to assess proposed acquisition of Figma by Adobe
- 01/23/23
- Adobe CEO sells $5.2M in common stock
- 01/12/23
- Adobe director sells $1.0M in common stock
- 01/09/23
- Cathie Wood's ARK Investment bought 11.6K shares of Adobe today
- $139.27 /
-8.365 (-5.67%) - 02/24/23 SVB Securities
- SVB downgrades Moderna to Underperform as COVID boom reverses
- 02/24/23 SVB Securities
- Moderna downgraded to Underperform from Market Perform at SVB Securities
- 02/23/23 Morgan Stanley
- Moderna price target lowered to $185 from $205 at Morgan Stanley
- 02/23/23 BofA
- Investors could become cautious in near-term on Moderna, says BofA
NVTS Navitas Semiconductor - 02/24/23 Deutsche Bank
- Navitas Semiconductor price target raised to $8 from $6 at Deutsche Bank
- 02/24/23 Baird
- Navitas Semiconductor price target raised to $10 from $8 at Baird
- 11/10/22 Deutsche Bank
- Navitas Semiconductor price target lowered to $6 from $7 at Deutsche Bank
- 11/10/22 Baird
- Navitas Semiconductor price target lowered to $8 from $12 at Baird
- 02/16/23 Citi
- Citi launches beverage, personal space with six buys, two sells
- 02/16/23 Citi
- Molson Coors initiated with a Neutral at Citi
- 02/07/23 Morgan Stanley
- Molson Coors assumed with an Equal Weight at Morgan Stanley
- 01/06/23 TD Cowen
- Molson Coors upgraded to Outperform from Market Perform at Cowen
- 02/07/23 Raymond James
- Ericsson downgraded to Market Perform from Outperform at Raymond James
- 01/31/23 UBS
- Ericsson price target lowered to SEK 65 from SEK 70 at UBS
- 01/24/23 JPMorgan
- Ericsson price target lowered to SEK 85 from SEK 101 at JPMorgan
- 01/23/23 Goldman Sachs
- Goldman downgrades Ericsson to Sell on declining wireless market
- $320.50 /
-26.42 (-7.62%) - 02/15/23 UBS
- Adobe price target raised to $400 from $350 at UBS
- 01/18/23 DA Davidson
- Adobe initiated with a Neutral at DA Davidson
- 01/17/23 DA Davidson
- Adobe initiated with a Neutral at DA Davidson
- 01/17/23 William Blair
- Adobe initiated with an Outperform at William Blair
- 09/23/22 Credit Suisse
- Cvent initiated with an Outperform at Credit Suisse
- 06/17/22 Morgan Stanley
- Cvent initiated with an Equal Weight at Morgan Stanley
- 05/10/22 Canaccord
- Cvent price target lowered to $8 from $11 at Canaccord
- 03/08/22 Colliers
- Cvent initiated with a Buy at Colliers
- 01/27/23 BMO Capital
- Blackstone price target raised to $92 from $85 at BMO Capital
- 01/27/23 Barclays
- Blackstone price target raised to $100 from $86 at Barclays
- 01/24/23 JPMorgan
- TPG downgraded to Neutral from Overweight at JPMorgan
- 01/24/23 JPMorgan
- Blackstone upgraded to Overweight from Neutral at JPMorgan
- 01/24/23 Wells Fargo
- Pioneer Natural initiated with an Underweight at Wells Fargo
- 01/24/23 Wells Fargo
- Pioneer Natural initiated with an Underweight at Wells Fargo
- 01/09/23 Mizuho
- Pioneer Natural assumed with a Buy at Mizuho
- 01/09/23 KeyBanc
- Pioneer Natural downgraded to Sector Weight from Overweight at KeyBanc
- $28.25 /
+3.005 (+11.90%) - 01/24/23 Wells Fargo
- Range Resources initiated with an Equal Weight at Wells Fargo
- 01/23/23 Benchmark
- Range Resources downgraded to Hold at Benchmark on buyback potential
- 01/23/23 Benchmark
- Range Resources downgraded to Hold from Buy at Benchmark
- 01/09/23 Mizuho
- Range Resources assumed with a Neutral at Mizuho
- 02/24/23 Morgan Stanley
- Block price target raised to $72 from $67 at Morgan Stanley
- 02/24/23 Needham
- Block price target raised to $95 from $80 at Needham
- 02/24/23 Wells Fargo
- Block price target raised to $105 from $96 at Wells Fargo
- 02/24/23 Baird
- Block price target raised to $92 from $85 at Baird
- $2,455.00 /
+25.9 (+1.07%) - 02/24/23 UBS
- Booking Holdings price target raised to $2,900 from $2,785 at UBS
- 02/24/23 Credit Suisse
- Booking Holdings price target raised to $2,850 from $2,600 at Credit Suisse
- 02/24/23 BofA
- Booking Holdings price target raised to $2,850 from $2,700 at BofA
- 02/24/23 JPMorgan
- Booking Holdings price target raised to $2,850 from $2,675 at JPMorgan
WBD Warner Bros. Discovery - 01/31/23 Macquarie
- Warner Bros. Discovery price target raised to $20 from $16 at Macquarie
- 01/30/23 Morgan Stanley
- Warner Bros. Discovery price target raised to $17 from $14 at Morgan Stanley
- 01/24/23 Atlantic Equities
- Atlantic sees 80% upside in Warner Bros. Discovery after analyzing merger
- 01/11/23 Guggenheim
- Guggenheim upgrades Warner Bros. Discovery to Buy, sees 31% potential upside
- $198.10 /
-10.045 (-4.83%) - 02/24/23 JPMorgan
- Boeing can still meet delivery target despite halt, says JPMorgan
- 02/03/23 RBC Capital
- Boeing downgraded to Sector Perform from Outperform at RBC Capital
- 01/30/23 Jefferies
- Boeing price target raised to $250 from $240 at Jefferies
- 01/26/23 Morgan Stanley
- Boeing remains a 'show me story,' says Morgan Stanley
- 02/08/23 Wells Fargo
- Goldman Sachs price target raised to $420 from $390 at Wells Fargo
- 01/18/23 Wells Fargo
- Goldman Sachs price target lowered to $390 from $400 at Wells Fargo
- 01/10/23 Odeon Capital
- Goldman Sachs upgraded to Hold from Sell at Odeon Capital
- 01/06/23 Morgan Stanley
- Goldman Sachs price target lowered to $356 from $384 at Morgan Stanley
- $297.42 /
-10.58 (-3.44%) - 02/24/23 Evercore ISI
- Domino's target lowered, removed from 'Tactical Underperform' list at Evercore
- 02/24/23 BMO Capital
- Domino's Pizza price target lowered to $380 from $430 at BMO Capital
- 02/24/23 Morgan Stanley
- Domino's Pizza price target lowered to $405 from $430 at Morgan Stanley
- 02/24/23 BTIG
- Domino's Pizza price target lowered to $400 from $460 at BTIG
- $12.98 /
+1.505 (+13.12%) - 02/24/23 Canaccord
- Kratos Defense upgraded to Buy at Canaccord on space and drone strength
- 02/24/23 Canaccord
- Kratos Defense upgraded to Buy from Hold at Canaccord
- 11/04/22 Canaccord
- Kratos Defense downgraded to Hold at Canaccord after guidance cut
- 11/04/22 Canaccord
- Kratos Defense downgraded to Hold from Buy at Canaccord
- 02/24/23 Canaccord
- Yeti price target lowered to $54 from $58 at Canaccord
- 02/24/23 Raymond James
- Yeti price target lowered to $45 from $55 at Raymond James
- 02/24/23 Baird
- Yeti price target lowered to $55 from $60 at Baird
- 02/24/23 Goldman Sachs
- Yeti downgraded to Neutral from Buy at Goldman Sachs
- 02/24/23 Barclays
- Zeta Global price target raised to $11 from $10 at Barclays
- 12/09/22 B. Riley
- B. Riley starts 'well positioned' Zeta with Buy, $13 target
- 12/09/22 B. Riley
- Zeta Global initiated with a Buy at B. Riley
- 11/21/22 Credit Suisse
- Zeta Global initiated with a Neutral at Credit Suisse
- 01/30/23 KeyBanc
- KeyBanc keeps Overweight on Farfetch, lowers price target to $11
- 12/15/22 Oppenheimer
- Farfetch price target lowered to $7 from $14 at Oppenheimer
- 12/05/22 TD Cowen
- Farfetch price target lowered to $8 from $11 at Cowen
- 12/02/22 Wells Fargo
- Farfetch price target lowered to $18 from $25 at Wells Fargo
- 02/24/23 Jefferies
- Esperion assumed at Buy from Hold at Jefferies
- 02/03/23 Morgan Stanley
- Esperion upgraded to Equal Weight from Underweight at Morgan Stanley
- 12/07/22 H.C. Wainwright
- H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint
- 08/03/22 Credit Suisse
- Esperion downgraded to Underperform from Neutral at Credit Suisse
FULC Fulcrum Therapeutics - 02/24/23 BofA
- Fulcrum Therapeutics downgraded to Underperform from Neutral at BofA
- 02/24/23 Oppenheimer
- Fulcrum clinical hold 'gut punch for shares,' says Oppenheimer
- 01/22/23 Piper Sandler
- Fulcrum Therapeutics price target raised to $21 from $18 at Piper Sandler
- 01/19/23 Oppenheimer
- Fulcrum Therapeutics price target lowered to $26 from $30 at Oppenheimer
- 02/24/23 SVB Securities
- Nektar price target lowered to $3 from $5 at SVB Securities
- 02/24/23 Jefferies
- Nektar downgraded to Underperform from Hold at Jefferies
- 11/29/22 Guggenheim
- Guggenheim starts Medicenna Therapeutics with a Buy on MDNA11 potential
- 08/08/22 JPMorgan
- Nektar downgraded to Underweight from Neutral at JPMorgan
- $18.86 /
+1.725 (+10.07%) - 02/24/23 Bernstein
- Beyond Meat price target raised to $18 from $10 at Bernstein
- 02/24/23 Mizuho
- Beyond Meat price target raised to $20 from $11 at Mizuho
- 02/24/23 JPMorgan
- Beyond Meat earnings report a 'positive surprise,' says JPMorgan
- 02/24/23 Piper Sandler
- Piper Sandler stays bearish on Beyond Meat after Q4 results
- 02/22/23 Credit Suisse
- Cinemark upgraded to Neutral from Underperform at Credit Suisse
- 02/09/23 Macquarie
- Macquarie raises price target on top theatre pick for 2023
- 01/12/23 JPMorgan
- Cinemark upgraded to Overweight from Neutral at JPMorgan
- 01/03/23 B. Riley
- Cinemark price target lowered to $13 from $16 at B. Riley
- 03/22/22 Northland
- MoneyGram downgraded to Market Perform at Northland on go-private deal
- 03/22/22 Northland
- MoneyGram downgraded to Market Perform from Outperform at Northland
- $12.21 /
-1.555 (-11.30%) - 02/15/23 Deutsche Bank
- DigitalBridge initiated with a Buy at Deutsche Bank
- 11/07/22 Raymond James
- DigitalBridge price target lowered to $34 from $38 at Raymond James
- 11/07/22 TD Cowen
- DigitalBridge price target lowered to $27 from $33 at Cowen
- 09/19/22 B. Riley
- DigitalBridge positive developments 'under the radar,' says B. Riley
- $24.01 /
+2.425 (+11.24%) - 10/10/22 Barclays
- Turning Point Brands downgraded to Equal Weight from Overweight at Barclays
- 08/31/22 Barclays
- Turning Point Brands price target lowered to $28 from $38 at Barclays
- 07/28/22 Craig-Hallum
- Turning Point Brands price target lowered to $45 from $50 at Craig-Hallum
- 07/28/22 TD Cowen
- Turning Point Brands price target lowered to $45 from $65 at Cowen
- 02/23/23
- Zeta Global announces long-term targets
- 02/23/23
- Zeta Global sees FY23 revenue $686M-$696M, consensus $671.63M
- 02/23/23
- Zeta Global sees Q1 revenue $149M-$151M, consensus $151.3M.
- 02/23/23
- Zeta Global reports Q4 EPS (36c) vs. (46c) last year
- 02/23/23
- Yeti sees FY23 adjusted EPS $2.12-$2.23, consensus $2.82
- 02/23/23
- Yeti reports Q4 adjusted EPS 78c, consensus 79c
WBD Warner Bros. Discovery - 02/23/23
- Warner Bros. Discovery sees FY23 adjusted EBITDA low- to mid-$11B range
- 02/23/23
- Warner Bros. Discovery reports Q4 EPS (86c), consensus (20c)
- 11/03/22
- Warner Bros. Discovery reports Q3 EPS (95c), consensus (21c)
- $24.01 /
+2.425 (+11.24%) - 02/24/23
- Turning Point Brands sees FY23 adjusted EBITDA $88M-$94M
- 02/24/23
- Turning Point Brands reports Q4 EPS 69c, consensus 58c
- 10/26/22
- Turning Point Brands reports Q3 adjusted EPS 72c, consensus 60c
- 10/17/22
- Turning Point Brands reports preliminary Q3 revenue $106M-$108M
- 02/21/23
- Molson Coors reports Q 4EPS $1.30, consensus $1.07
- 11/01/22
- Molson Coors reports Q3 EPS $1.32, consensus $1.36
- 02/23/23
- Block reports Q4 EPS 22c, consensus 30c
- 02/23/23
- Notable companies reporting after market close
- 11/03/22
- Block reports Q3 adjusted EPS 42c, consensus 23c
- 11/03/22
- Notable companies reporting after market close
- $28.25 /
+3.005 (+11.90%) - 10/24/22
- Range Resources reports Q3 adjusted EPS $1.37, consensus $1.39
- 02/22/23
- Pioneer Natural reports Q4 adjusted EPS $5.91, consensus $5.77
- 10/27/22
- Pioneer Natural reports Q3 adjusted EPS $7.48, consensus $7.50
NVTS Navitas Semiconductor - 02/23/23
- Navitas Semiconductor sees Q1 revenue flat, consensus $13.05M
- 02/23/23
- Navitas Semiconductor reports Q4 EPS (6c), consensus (8c)
- 11/09/22
- Navitas Semiconductor sees Q4 revenue $11M-$13M, consensus $14.06M
- 11/09/22
- Navitas Semiconductor reports Q3 EPS (7c), consensus (7c)
- 11/03/22
- Nektar reports Q3 EPS (31c), consensus (45c)
- $139.27 /
-8.365 (-5.67%) - 02/23/23
- Moderna reports Q4 EPS $3.61, consensus $4.67
- 02/22/23
- Notable companies reporting before tomorrow's open
- 11/03/22
- Moderna reports Q3 EPS $2.53, consensus $3.29
- 02/24/23
- MoneyGram reports Q4 adjusted EPS 23c vs. 22c last year
- $12.98 /
+1.505 (+13.12%) - 02/23/23
- Kratos Defense reports Q4 EPS 8c, consensus 8c
- 11/04/22
- Kratos Defense lowers FY22 revenue view to $880M-$900M from $890M-$930M
- 11/04/22
- Kratos Defense sees Q4 revenue $231M-251M, consensus $259.1M
- 11/03/22
- Kratos Defense reports Q3 EPS 8c, consensus 7c
- 01/17/23
- Goldman Sachs reports Q4 EPS $3.32, consensus $5.48
- 10/18/22
- Goldman Sachs reports Q3 EPS $8.25, consensus $7.69
- 10/17/22
- Notable companies reporting before tomorrow's open
FULC Fulcrum Therapeutics - 11/08/22
- Fulcrum Therapeutics reports Q3 EPS (51c), consensus (61c)
- 02/23/23
- Farfetch sees FY23 adjusted EBITDA margin 1%-3%
- 02/23/23
- Farfetch reports Q4 adjusted EPS (25c), consensus (47c)
- 11/17/22
- Farfetch reports Q3 adjusted EPS (24c), consensus (28c)
- 02/21/23
- Esperion reports Q4 EPS (76c), consensus (84c)
- 01/08/23
- Esperion reports preliminary Q4 revenue $14.4M-$15.1M, consensus $21.07M
- 11/01/22
- Esperion reports Q3 EPS (81c), consensus (92c)
- 01/20/23
- Ericsson reports Q4 EPS SEK 1.82 vs. SEK 3.02 last year
- 10/20/22
- Ericsson reports Q3 EPS SEK 1.56 vs. SEK 1.73 last year
- $297.42 /
-10.58 (-3.44%) - 02/23/23
- Domino's Pizza reports Q4 EPS $4.43, consensus $3.95
- 10/13/22
- Domino's Pizza reports Q3 EPS $2.79, consensus $2.97
- $12.21 /
-1.555 (-11.30%) - 02/24/23
- DigitalBridge reports Q4 distributable EPS (7c), consensus (33c)
- 11/04/22
- DigitalBridge reports Q3 EPS (39c), consensus (21c)
- 11/03/22
- Cvent raises FY22 revenue view to $628.9M-$629.9M from $624.9M-$628.4M
- 11/03/22
- Cvent sees Q4 revenue $169.3M-$170.3M, consensus $169.29M
- 11/03/22
- Cvent reports Q3 EPS (4c), consensus 4c
- 02/24/23
- Cinemark reports Q4 EPS (82c), consensus (21c)
- 02/23/23
- Notable companies reporting before tomorrow's open
- 11/04/22
- Cinemark reports Q3 EPS (20c), consensus (14c)
- $18.86 /
+1.725 (+10.07%) - 02/23/23
- Beyond Meat sees FY23 revenue $375M-$415M, consensus $394.2M
- 02/23/23
- Beyond Meat reports Q4 EPS ($1.05), consensus ($1.18)
- 11/09/22
- Beyond Meat cuts FY22 revenue view to $400M-$425M from $470M-$520M
- 01/27/23
- Blackstone reports Q4 distributable EPS $1.07 vs. $1.71 y/y
- 01/25/23
- Notable companies reporting before tomorrow's open
- 01/25/23
- UC Investments to invest additional $500M in BREIT common shares
- $2,455.00 /
+25.9 (+1.07%) - 02/23/23
- Booking Holdings reports Q4 adjusted EPS $24.74, consensus $22.24
- 11/02/22
- Booking Holdings reports Q3 adjusted EPS $53.03, consensus $49.85
- 11/02/22
- Notable companies reporting after market close
- $198.10 /
-10.045 (-4.83%) - 01/25/23
- Boeing reports Q4 core EPS ($1.75), consensus 26c
- 01/24/23
- Notable companies reporting before tomorrow's open
- 10/26/22
- Boeing reports Q3 core EPS ($6.18), consensus 2c
- $320.50 /
-26.42 (-7.62%) - 12/15/22
- Adobe backs FY23 adjusted EPS view $15.15-$15.45, consensus $15.25
- 12/15/22
- Adobe sees Q1 adjusted EPS $3.65-$3.70, consensus $3.64
- 12/15/22
- Adobe reports Q4 adjusted EPS $3.60, consensus $3.50
- 12/15/22
- Notable companies reporting after market close
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - $10.16 /
+1.095 (+12.09%) - 02/24/23
- Zeta Global rises 12.4%
- 02/24/23
- Zeta Global rises 12.0%
- 11/30/22
- Zeta Global announces record results for ZMP
- 02/23/23
- Yeti falls 9% to $36.02 after Q4 results, FY23 guidance miss estimates
- 02/16/23
- Yeti appoints Mike McMullen as CFO
- 02/06/23
- Yeti identifies a 'potential safety concern' regarding certain products
- 01/24/23
- YETI Holdings trading resumes
WBD Warner Bros. Discovery - 02/23/23
- Warner Bros. says 'Hogwarts Legacy' sells over 12M units in first two weeks
- 02/23/23
- Warner Bros. Discovery reports Q4 cash provided by operating activities $2.85B
- 02/23/23
- Warner Bros. Discovery reports 96.1M global DTC subscribers at end of Q4
- 02/12/23
- Fly Intel: Top five weekend stock stories
- 02/23/23
- Turning Point Brands raises quarterly dividend 8% to 6.5c per share
- 10/26/22
- Turning Point Brands sees FY22 adjusted EBITDA $96M-$99M
- 10/17/22
- Turning Point Brands sees FY22 adjusted EBITDA $96M-$99M
- 10/17/22
- Turning Point Brands CEO Yavor Efremov resigns, Graham Purdy succeeds
- 02/13/23
- U.S. video game spending fell 5% y/y in January, says NPD
- 01/19/23
- Sony announces additional games coming to PlayStation VR2
- 01/17/23
- U.S. video game consumer spending rose 2% y/y in December, says NPD
- 12/27/22
- China stocks rising with borders set to reopen on January 8
- 01/19/23
- Complexity Gaming renews partnership with Miller Lite
- 10/06/22
- Molson Coors announces new partnership with the Professional Pickleball Assoc
- 09/29/22
- Molson Coors expands agreement with Coca-Cola to develop Topo Chico Spirited
- 02/23/23
- Block sees FY23 adjusted EBITEA at $1.3B vs. $991M in FY22
- 02/23/23
- Block sees combined company gross profit in January-February up 25%
- 02/23/23
- Block reports Q4 cash app gross profit $848M vs. $518M last year
- 02/23/23
- Block reports Q4 gross payment volume $48.6B vs. $42.6B last year
NVTS Navitas Semiconductor - 02/13/23
- Navitas Semiconductor announces GaNFast tech in OnePlus 11 5G smartphone
- 02/01/23
- Navitas Semiconductor welcomes visitors to 'Planet Navitas'
- 01/19/23
- Navitas acquires silicon control IC from JV from Halo for price of $20M in stock
- 12/28/22
- 'Navitas Presents:' Partner Insights at CES 2024
- 02/23/23
- Nektar down 31% afterhours after update on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading resumes
- 02/23/23
- Nektar reports Phase 2 data on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading halted, news pending
- $141.87 /
-5.765 (-3.90%) - 02/23/23
- Moderna says $2.8B remaining under latest buyback authorization
- 02/23/23
- Moderna backs forecast of $5B in COVID-19 sales contracted for 2023 delivery
- 02/23/23
- Moderna sees FY23 CapEx at about $1.0B and R&D expense at about $4.5B
- 02/23/23
- Moderna, Merck granted FDA Breakthrough Therapy Designation for mRNA-4157/V940
- 01/30/23
- MoneyGram provides update on acquisition by MDP
- 01/25/23
- MoneyGram announces strategic partnership with Astra Tech
- 12/21/22
- MoneyGram merger with Madison Dearborn receives penultimate regulatory approval
- 11/14/22
- MoneyGram announces partnership with Beyon Money
- 02/21/23
- Meta Platforms COO sells $2.27M in common stock
- 02/20/23
- Fly Intel: Top five weekend stock stories
- 02/19/23
- Meta testing subscription service for $11.99 a month
- 02/16/23
- TikTok debuts 'TikTok Trivia,' a live 5-day trivia game with prize pool
- 02/23/23
- Kratos Defense receives $49.57M Navy FRP contract
- 02/23/23
- Kratos Defense sees total FY23 CapEx $45M-$50M
- 02/22/23
- Kratos Defense releases OpenEdge products
- 01/10/23
- Kratos Defense receives Mayhem hypersonic missile program contract award
FULC Fulcrum Therapeutics - 02/24/23
- Fulcrum Therapeutics announces clinical hold on FTX-6058 in SCD
- 01/24/23
- Fulcrum Therapeutics jumps 7% as Ra Capital discloses $25M purchase
- 01/04/23
- Fulcrum Therapeutics sees cash runway into late 2024
- 01/04/23
- Fulcrum Therapeutics provides business update, upcoming milestones
- 02/24/23
- Farfetch rises 13.0%
- 02/23/23
- Farfetch CFO Jordan to step down by end of 2023
- 01/18/23
- Farfetch announces changes to leadership team
- 12/29/22
- Farfetch rises 11.7%
- 01/11/23
- RFK Racing enters team-wide partnership with Esperion
- 12/07/22
- Esperion announces CLEAR cardiovascular outcomes trial of NEXLETOL
- 11/16/22
- Esperion promotes Ben Halladay to CFO role
- 08/26/22
- Esperion: NEXLETOL recommended as oral non-statin therapy by ACC task force
- 01/12/23
- Ericsson makes $220M provision in Q4 for potential DPA breach resolution
- 01/11/23
- Ericsson Nomination Committee proposes board, Jan Carlson as chairman
- 01/10/23
- Intel unveils 4th Gen Xeon Scalable processors, Xeon CPU Max Series
- 12/15/22
- Ericsson provides long-term targets and strategy on 2022 Capital Markets Day
- 02/23/23
- Domino's Pizza falls -10.2%
- 02/23/23
- Domino's Pizza sees FY23 CapEx $90M-$100M
- 02/23/23
- Domino's Pizza cuts two-to three-year outlook for global retail sales growth
- 12/15/22
- Domino's Pizza to enter Uruguay and Latvia
- 09/21/22
- DigitalBridge CEO buys $487K in common stock
- 09/14/22
- DigitalBridge reinstates dividend with 1c per share
- 02/24/23
- Cinemark falls 5% to $12.36 after Q4 results miss estimates
- 02/15/23
- Cinemark founder Lee Roy Mitchell to retire from board
- 01/24/23
- Cinemark and EntTelligence extend service agreement
- 11/23/22
- Film exhibitor stocks higher after report of Amazon spending plans
- 02/23/23
- Beyond Meat 'encouraged' by 14% improvement in margin expansion
- 02/23/23
- Beyond Meat up 15% after reporting Q4 earnings results
- 01/03/23
- Beyond Meat says 'Beyond Steak' now available at select Costco locations
- 12/29/22
- Beyond Meat rises after McDonald's UK&I announces 'Double McPlant'
- $2,432.01 /
+2.91 (+0.12%) - 02/23/23
- Booking announces $20B share repurchase authorization
- 02/23/23
- Booking Holdings CEO says 'proud of our company's performance' in 2022
- 02/14/23
- Lone Pine exited PayPal, initiated AMD position during Q4
- 02/13/23
- Soros Fund buys Horizon Therapeutics, exits BNY Mellon in Q4
- 02/23/23
- American Airlines chairman Doug Parker to retire, Greg Smith to succeed
- 02/23/23
- Boeing drops 2% to $204 after WSJ report of halted Dreamliner deliveries
- 02/23/23
- Boeing sees completing new-build production of F/A-18 Super Hornet in late 2025
- 02/15/23
- Boeing sees clearing 100 Dreamliners from storage by end of 2024, says CFO
- $321.50 /
-25.42 (-7.33%) - 02/15/23
- European Commission to assess proposed acquisition of Figma by Adobe
- 01/23/23
- Adobe CEO sells $5.2M in common stock
- 01/12/23
- Adobe director sells $1.0M in common stock
- 01/09/23
- Cathie Wood's ARK Investment bought 11.6K shares of Adobe today
- 02/24/23 Morgan Stanley
- Block price target raised to $72 from $67 at Morgan Stanley
- 02/24/23 Needham
- Block price target raised to $95 from $80 at Needham
- 02/24/23 Wells Fargo
- Block price target raised to $105 from $96 at Wells Fargo
- 02/24/23 Baird
- Block price target raised to $92 from $85 at Baird
- $2,432.01 /
+2.91 (+0.12%) - 02/24/23 UBS
- Booking Holdings price target raised to $2,900 from $2,785 at UBS
- 02/24/23 Credit Suisse
- Booking Holdings price target raised to $2,850 from $2,600 at Credit Suisse
- 02/24/23 BofA
- Booking Holdings price target raised to $2,850 from $2,700 at BofA
- 02/24/23 JPMorgan
- Booking Holdings price target raised to $2,850 from $2,675 at JPMorgan
WBD Warner Bros. Discovery - 01/31/23 Macquarie
- Warner Bros. Discovery price target raised to $20 from $16 at Macquarie
- 01/30/23 Morgan Stanley
- Warner Bros. Discovery price target raised to $17 from $14 at Morgan Stanley
- 01/24/23 Atlantic Equities
- Atlantic sees 80% upside in Warner Bros. Discovery after analyzing merger
- 01/11/23 Guggenheim
- Guggenheim upgrades Warner Bros. Discovery to Buy, sees 31% potential upside
- 02/24/23 JPMorgan
- Boeing can still meet delivery target despite halt, says JPMorgan
- 02/03/23 RBC Capital
- Boeing downgraded to Sector Perform from Outperform at RBC Capital
- 01/30/23 Jefferies
- Boeing price target raised to $250 from $240 at Jefferies
- 01/26/23 Morgan Stanley
- Boeing remains a 'show me story,' says Morgan Stanley
- $321.50 /
-25.42 (-7.33%) - 02/15/23 UBS
- Adobe price target raised to $400 from $350 at UBS
- 01/18/23 DA Davidson
- Adobe initiated with a Neutral at DA Davidson
- 01/17/23 DA Davidson
- Adobe initiated with a Neutral at DA Davidson
- 01/17/23 William Blair
- Adobe initiated with an Outperform at William Blair
- 02/24/23 Evercore ISI
- Domino's target lowered, removed from 'Tactical Underperform' list at Evercore
- 02/24/23 BMO Capital
- Domino's Pizza price target lowered to $380 from $430 at BMO Capital
- 02/24/23 Morgan Stanley
- Domino's Pizza price target lowered to $405 from $430 at Morgan Stanley
- 02/24/23 BTIG
- Domino's Pizza price target lowered to $400 from $460 at BTIG
- 02/24/23 Canaccord
- Kratos Defense upgraded to Buy at Canaccord on space and drone strength
- 02/24/23 Canaccord
- Kratos Defense upgraded to Buy from Hold at Canaccord
- 11/04/22 Canaccord
- Kratos Defense downgraded to Hold at Canaccord after guidance cut
- 11/04/22 Canaccord
- Kratos Defense downgraded to Hold from Buy at Canaccord
- 02/24/23 Canaccord
- Yeti price target lowered to $54 from $58 at Canaccord
- 02/24/23 Raymond James
- Yeti price target lowered to $45 from $55 at Raymond James
- 02/24/23 Baird
- Yeti price target lowered to $55 from $60 at Baird
- 02/24/23 Goldman Sachs
- Yeti downgraded to Neutral from Buy at Goldman Sachs
- $141.87 /
-5.765 (-3.90%) - 02/24/23 SVB Securities
- SVB downgrades Moderna to Underperform as COVID boom reverses
- 02/24/23 SVB Securities
- Moderna downgraded to Underperform from Market Perform at SVB Securities
- 02/23/23 Morgan Stanley
- Moderna price target lowered to $185 from $205 at Morgan Stanley
- 02/23/23 BofA
- Investors could become cautious in near-term on Moderna, says BofA
- 02/16/23 Citi
- Citi launches beverage, personal space with six buys, two sells
- 02/16/23 Citi
- Molson Coors initiated with a Neutral at Citi
- 02/07/23 Morgan Stanley
- Molson Coors assumed with an Equal Weight at Morgan Stanley
- 01/06/23 TD Cowen
- Molson Coors upgraded to Outperform from Market Perform at Cowen
- 02/07/23 Raymond James
- Ericsson downgraded to Market Perform from Outperform at Raymond James
- 01/31/23 UBS
- Ericsson price target lowered to SEK 65 from SEK 70 at UBS
- 01/24/23 JPMorgan
- Ericsson price target lowered to SEK 85 from SEK 101 at JPMorgan
- 01/23/23 Goldman Sachs
- Goldman downgrades Ericsson to Sell on declining wireless market
BTI British American Tobacco - 02/13/23 JPMorgan
- British American Tobacco price target lowered to 3,600 GBp at JPMorgan
- 02/13/23 Credit Suisse
- British American Tobacco price target lowered to 3,900 GBp at Credit Suisse
- 01/11/23 Morgan Stanley
- British American Tobacco price target lowered to 3,900 GBp at Morgan Stanley
- 12/01/22 JPMorgan
- British American Tobacco price target lowered to 4,000 GBp at JPMorgan
- 02/21/23 BofA
- BofA sees 12M potential subscriber opportunity for Meta Verified
- 02/13/23 BofA
- BofA sees room for additional efficiencies at Meta
- 02/10/23 Tigress Financial
- Meta Platforms price target raised to $285 from $260 at Tigress Financial
- 02/08/23 Loop Capital
- Meta Platforms price target raised to $188 from $165 at Loop Capital
- 01/25/23 Barclays
- Tencent price target raised to $48 from $36 at Barclays
- 01/05/23 Mizuho
- Tencent price target raised to HK$330 from HK$300 at Mizuho
- 11/02/22 Morgan Stanley
- Tencent named a 'Catalyst Driven Idea' at Morgan Stanley
- 10/28/22 Barclays
- Tencent price target lowered to $31 from $44 at Barclays
NVTS Navitas Semiconductor - 02/24/23 Deutsche Bank
- Navitas Semiconductor price target raised to $8 from $6 at Deutsche Bank
- 02/24/23 Baird
- Navitas Semiconductor price target raised to $10 from $8 at Baird
- 11/10/22 Deutsche Bank
- Navitas Semiconductor price target lowered to $6 from $7 at Deutsche Bank
- 11/10/22 Baird
- Navitas Semiconductor price target lowered to $8 from $12 at Baird
- $10.16 /
+1.095 (+12.09%) - 02/24/23 Barclays
- Zeta Global price target raised to $11 from $10 at Barclays
- 12/09/22 B. Riley
- B. Riley starts 'well positioned' Zeta with Buy, $13 target
- 12/09/22 B. Riley
- Zeta Global initiated with a Buy at B. Riley
- 11/21/22 Credit Suisse
- Zeta Global initiated with a Neutral at Credit Suisse
- 01/30/23 KeyBanc
- KeyBanc keeps Overweight on Farfetch, lowers price target to $11
- 12/15/22 Oppenheimer
- Farfetch price target lowered to $7 from $14 at Oppenheimer
- 12/05/22 TD Cowen
- Farfetch price target lowered to $8 from $11 at Cowen
- 12/02/22 Wells Fargo
- Farfetch price target lowered to $18 from $25 at Wells Fargo
- 02/24/23 Jefferies
- Esperion assumed at Buy from Hold at Jefferies
- 02/03/23 Morgan Stanley
- Esperion upgraded to Equal Weight from Underweight at Morgan Stanley
- 12/07/22 H.C. Wainwright
- H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint
- 08/03/22 Credit Suisse
- Esperion downgraded to Underperform from Neutral at Credit Suisse
FULC Fulcrum Therapeutics - 02/24/23 Oppenheimer
- Fulcrum clinical hold 'gut punch for shares,' says Oppenheimer
- 01/22/23 Piper Sandler
- Fulcrum Therapeutics price target raised to $21 from $18 at Piper Sandler
- 01/19/23 Oppenheimer
- Fulcrum Therapeutics price target lowered to $26 from $30 at Oppenheimer
- 01/04/23 Piper Sandler
- Fulcrum reports 'encouraging' Phase 1b data for FTX-6058, says Piper Sandler
- 02/24/23 SVB Securities
- Nektar price target lowered to $3 from $5 at SVB Securities
- 02/24/23 Jefferies
- Nektar downgraded to Underperform from Hold at Jefferies
- 11/29/22 Guggenheim
- Guggenheim starts Medicenna Therapeutics with a Buy on MDNA11 potential
- 08/08/22 JPMorgan
- Nektar downgraded to Underweight from Neutral at JPMorgan
- 02/24/23 Bernstein
- Beyond Meat price target raised to $18 from $10 at Bernstein
- 02/24/23 Mizuho
- Beyond Meat price target raised to $20 from $11 at Mizuho
- 02/24/23 JPMorgan
- Beyond Meat earnings report a 'positive surprise,' says JPMorgan
- 02/24/23 Piper Sandler
- Piper Sandler stays bearish on Beyond Meat after Q4 results
- 02/22/23 Credit Suisse
- Cinemark upgraded to Neutral from Underperform at Credit Suisse
- 02/09/23 Macquarie
- Macquarie raises price target on top theatre pick for 2023
- 01/12/23 JPMorgan
- Cinemark upgraded to Overweight from Neutral at JPMorgan
- 01/03/23 B. Riley
- Cinemark price target lowered to $13 from $16 at B. Riley
- 03/22/22 Northland
- MoneyGram downgraded to Market Perform at Northland on go-private deal
- 03/22/22 Northland
- MoneyGram downgraded to Market Perform from Outperform at Northland
- 02/15/23 Deutsche Bank
- DigitalBridge initiated with a Buy at Deutsche Bank
- 11/07/22 Raymond James
- DigitalBridge price target lowered to $34 from $38 at Raymond James
- 11/07/22 TD Cowen
- DigitalBridge price target lowered to $27 from $33 at Cowen
- 09/19/22 B. Riley
- DigitalBridge positive developments 'under the radar,' says B. Riley
- 10/10/22 Barclays
- Turning Point Brands downgraded to Equal Weight from Overweight at Barclays
- 08/31/22 Barclays
- Turning Point Brands price target lowered to $28 from $38 at Barclays
- 07/28/22 Craig-Hallum
- Turning Point Brands price target lowered to $45 from $50 at Craig-Hallum
- 07/28/22 TD Cowen
- Turning Point Brands price target lowered to $45 from $65 at Cowen
- $10.16 /
+1.095 (+12.09%) - 02/23/23
- Zeta Global announces long-term targets
- 02/23/23
- Zeta Global sees FY23 revenue $686M-$696M, consensus $671.63M
- 02/23/23
- Zeta Global sees Q1 revenue $149M-$151M, consensus $151.3M.
- 02/23/23
- Zeta Global reports Q4 EPS (36c) vs. (46c) last year
- 02/23/23
- Yeti sees FY23 adjusted EPS $2.12-$2.23, consensus $2.82
- 02/23/23
- Yeti reports Q4 adjusted EPS 78c, consensus 79c
WBD Warner Bros. Discovery - 02/23/23
- Warner Bros. Discovery sees FY23 adjusted EBITDA low- to mid-$11B range
- 02/23/23
- Warner Bros. Discovery reports Q4 EPS (86c), consensus (20c)
- 11/03/22
- Warner Bros. Discovery reports Q3 EPS (95c), consensus (21c)
- 02/24/23
- Turning Point Brands sees FY23 adjusted EBITDA $88M-$94M
- 02/24/23
- Turning Point Brands reports Q4 EPS 69c, consensus 58c
- 10/26/22
- Turning Point Brands reports Q3 adjusted EPS 72c, consensus 60c
- 10/17/22
- Turning Point Brands reports preliminary Q3 revenue $106M-$108M
- 02/21/23
- Molson Coors reports Q 4EPS $1.30, consensus $1.07
- 11/01/22
- Molson Coors reports Q3 EPS $1.32, consensus $1.36
- 02/23/23
- Block reports Q4 EPS 22c, consensus 30c
- 02/23/23
- Notable companies reporting after market close
- 11/03/22
- Block reports Q3 adjusted EPS 42c, consensus 23c
- 11/03/22
- Notable companies reporting after market close
NVTS Navitas Semiconductor - 02/23/23
- Navitas Semiconductor sees Q1 revenue flat, consensus $13.05M
- 02/23/23
- Navitas Semiconductor reports Q4 EPS (6c), consensus (8c)
- 11/09/22
- Navitas Semiconductor sees Q4 revenue $11M-$13M, consensus $14.06M
- 11/09/22
- Navitas Semiconductor reports Q3 EPS (7c), consensus (7c)
- 11/03/22
- Nektar reports Q3 EPS (31c), consensus (45c)
- $141.87 /
-5.765 (-3.90%) - 02/23/23
- Moderna reports Q4 EPS $3.61, consensus $4.67
- 11/03/22
- Moderna reports Q3 EPS $2.53, consensus $3.29
- 02/24/23
- MoneyGram reports Q4 adjusted EPS 23c vs. 22c last year
- 02/01/23
- Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B
- 02/01/23
- Meta Platforms reports Q4 EPS $1.76, consensus $2.22
- 02/01/23
- Notable companies reporting after market close
- 11/09/22
- Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B
- 02/23/23
- Kratos Defense reports Q4 EPS 8c, consensus 8c
- 11/04/22
- Kratos Defense lowers FY22 revenue view to $880M-$900M from $890M-$930M
- 11/04/22
- Kratos Defense sees Q4 revenue $231M-251M, consensus $259.1M
- 11/03/22
- Kratos Defense reports Q3 EPS 8c, consensus 7c
FULC Fulcrum Therapeutics - 11/08/22
- Fulcrum Therapeutics reports Q3 EPS (51c), consensus (61c)
- 02/23/23
- Farfetch sees FY23 adjusted EBITDA margin 1%-3%
- 02/23/23
- Farfetch reports Q4 adjusted EPS (25c), consensus (47c)
- 11/17/22
- Farfetch reports Q3 adjusted EPS (24c), consensus (28c)
- 02/21/23
- Esperion reports Q4 EPS (76c), consensus (84c)
- 01/08/23
- Esperion reports preliminary Q4 revenue $14.4M-$15.1M, consensus $21.07M
- 11/01/22
- Esperion reports Q3 EPS (81c), consensus (92c)
- 01/20/23
- Ericsson reports Q4 EPS SEK 1.82 vs. SEK 3.02 last year
- 10/20/22
- Ericsson reports Q3 EPS SEK 1.56 vs. SEK 1.73 last year
- 02/23/23
- Domino's Pizza reports Q4 EPS $4.43, consensus $3.95
- 02/22/23
- Notable companies reporting before tomorrow's open
- 10/13/22
- Domino's Pizza reports Q3 EPS $2.79, consensus $2.97
- 02/24/23
- DigitalBridge reports Q4 distributable EPS (7c), consensus (33c)
- 11/04/22
- DigitalBridge reports Q3 EPS (39c), consensus (21c)
- 02/24/23
- Cinemark reports Q4 EPS (82c), consensus (21c)
- 02/23/23
- Notable companies reporting before tomorrow's open
- 11/04/22
- Cinemark reports Q3 EPS (20c), consensus (14c)
- 02/23/23
- Beyond Meat sees FY23 revenue $375M-$415M, consensus $394.2M
- 02/23/23
- Beyond Meat reports Q4 EPS ($1.05), consensus ($1.18)
- 11/09/22
- Beyond Meat cuts FY22 revenue view to $400M-$425M from $470M-$520M
- $2,432.01 /
+2.91 (+0.12%) - 02/23/23
- Booking Holdings reports Q4 adjusted EPS $24.74, consensus $22.24
- 11/02/22
- Booking Holdings reports Q3 adjusted EPS $53.03, consensus $49.85
- 11/02/22
- Notable companies reporting after market close
- 01/25/23
- Boeing reports Q4 core EPS ($1.75), consensus 26c
- 01/24/23
- Notable companies reporting before tomorrow's open
- 10/26/22
- Boeing reports Q3 core EPS ($6.18), consensus 2c
- $321.50 /
-25.42 (-7.33%) - 12/15/22
- Adobe backs FY23 adjusted EPS view $15.15-$15.45, consensus $15.25
- 12/15/22
- Adobe sees Q1 adjusted EPS $3.65-$3.70, consensus $3.64
- 12/15/22
- Adobe reports Q4 adjusted EPS $3.60, consensus $3.50
- 12/15/22
- Notable companies reporting after market close
|
On The Fly
|
Want to get stock-moving… ShowHide Related Items >><< - 02/23/23
- Yeti falls 9% to $36.02 after Q4 results, FY23 guidance miss estimates
- 02/16/23
- Yeti appoints Mike McMullen as CFO
- 02/06/23
- Yeti identifies a 'potential safety concern' regarding certain products
- 01/24/23
- YETI Holdings trading resumes
- 01/30/23
- Vipshop falls -8.5%
- 12/27/22
- China stocks rising with borders set to reopen on January 8
- 12/23/22
- PCAOB chair 'applauds' Congressional action to shorten HFCAA timeline
- 09/02/22
- Vipshop falls -6.3%
- 02/23/23
- Block sees FY23 adjusted EBITEA at $1.3B vs. $991M in FY22
- 02/23/23
- Block sees combined company gross profit in January-February up 25%
- 02/23/23
- Block reports Q4 cash app gross profit $848M vs. $518M last year
- 02/23/23
- Block reports Q4 gross payment volume $48.6B vs. $42.6B last year
- 02/23/23
- Nektar down 31% afterhours after update on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading resumes
- 02/23/23
- Nektar reports Phase 2 data on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading halted, news pending
- 02/06/23
- NeoGenomics announces results from study of RaDaR assay
- 12/05/22
- NeoGenomics names Jeffrey Sherman as new CFO
- 11/21/22
- NeoGenomics presents new data on RaDaR Assay across early breast cancer
- 11/18/22
- NeoGenomics, ImmunoGen launche new program for ovarian cancer patients
- $143.20 /
-4.435 (-3.00%) - 02/23/23
- Moderna says $2.8B remaining under latest buyback authorization
- 02/23/23
- Moderna backs forecast of $5B in COVID-19 sales contracted for 2023 delivery
- 02/23/23
- Moderna sees FY23 CapEx at about $1.0B and R&D expense at about $4.5B
- 02/23/23
- Moderna, Merck granted FDA Breakthrough Therapy Designation for mRNA-4157/V940
- 02/24/23
- BetMGM announces pledge to feature responsible gaming messages
- 02/16/23
- Cherokee Nation Businesses completes acquisition of Gold Strike Casino Resort
- 02/16/23
- Anaxi enters strategic partnership with BetMGM for Aristocrat content
- 02/08/23
- MGM Resorts CEO says 'strong momentum in our business'
- 02/13/23
- Eli Lilly to supply API for insulin at reduced price to IABL
- 01/27/23
- Eli Lilly says FDA approves Jaypirca
- 01/24/23
- Eli Lilly trading resumes
- 02/23/23
- Kratos Defense receives $49.57M Navy FRP contract
- 02/23/23
- Kratos Defense sees total FY23 CapEx $45M-$50M
- 02/22/23
- Kratos Defense releases OpenEdge products
- 01/10/23
- Kratos Defense receives Mayhem hypersonic missile program contract award
- 02/23/23
- HashiCorp exec sells $1.16M in common stock
- 02/01/23
- PowerSchool appoints Paul Brook as CCO
- 12/07/22
- HashiCorp jumps 10% to $29.43 after Q3 earnings beat and guidance raise
- 10/19/22
- Intel announces new cloud collaboration with HashiCorp
- 01/11/23
- RFK Racing enters team-wide partnership with Esperion
- 12/07/22
- Esperion announces CLEAR cardiovascular outcomes trial of NEXLETOL
- 11/16/22
- Esperion promotes Ben Halladay to CFO role
- 08/26/22
- Esperion: NEXLETOL recommended as oral non-statin therapy by ACC task force
- 12/20/22
- Erasca announces first patient dosed in HERKULES-1 Phase 1b trial
- 12/13/22
- Erasca announces FDA clearance of IND application for ERAS-3490
- 12/09/22
- Erasca announces pricing of underwritten offering of common stock
- 12/09/22
- Erasca, Novartis enter worldwide license agreement for naporafenib
- 02/23/23
- Domino's Pizza falls -10.2%
- 02/23/23
- Domino's Pizza sees FY23 CapEx $90M-$100M
- 02/23/23
- Domino's Pizza cuts two-to three-year outlook for global retail sales growth
- 12/15/22
- Domino's Pizza to enter Uruguay and Latvia
- 02/23/23
- Fisker names ChargePoint as North America partner for EV charging stations
- 01/31/23
- Stem and ChargePoint to develop eMobility offering for EV charging stations
- 01/24/23
- ChargePoint Holdings trading resumes
- 01/24/23
- ChargePoint Holdings trading halted, volatility trading pause
- 02/23/23
- C4 Therapeutics announces upcoming milestones
- 01/30/23
- C4 Therapeutics announces first patient dosed in Phase 1/2 trial of CFT1946
- 01/09/23
- C4 Therapeutics expects cash to fund operations to end of 2024
- 01/09/23
- C4 Therapeutics announces 2023 strategic priorities
- 02/21/23
- Bowlero CEO sells $5.30M in common stock
- 01/24/23
- Bowlero CEO sells $2.76M in common stock
- 01/19/23
- Bowlero CEO sells $1.0M in common stock
- 01/17/23
- Bowlero CEO sells $6.78M in common stock
- 02/21/23
- Alnylam announces FDA acceptance of patisiran sNDA
- 01/05/23
- Alnylam names Amy Schulman board chair
- 12/21/22
- Alnylam submits CTA application for type 2 diabetes treatment ALN-KHK
- 12/08/22
- Alnylam submits supplemental NDA to FDA for Onpattro
- 01/27/23
- Arbutus Biopharma board member Tram Tran resigns
- 01/05/23
- Arbutus Biopharma announces 2023 corporate objectives
- 12/13/22
- Arbutus Biopharma completes enrollment in Phase 2 trial with AB-729, NA therapy
- 11/09/22
- Arbutus Biopharma expects cash to fund operations into 2Q24
- 02/24/23 Morgan Stanley
- Block price target raised to $72 from $67 at Morgan Stanley
- 02/24/23 Needham
- Block price target raised to $95 from $80 at Needham
- 02/24/23 Wells Fargo
- Block price target raised to $105 from $96 at Wells Fargo
- 02/24/23 Baird
- Block price target raised to $92 from $85 at Baird
- 02/24/23 TD Cowen
- NeoGenomics price target raised to $20 from $14 at Cowen
- 02/24/23 Benchmark
- Benchmark upgrades NeoGenomics to Buy on 'credible' plan
- 02/24/23 Benchmark
- NeoGenomics upgraded to Buy from Hold at Benchmark
- 02/01/23 Needham
- Needham upgrades NeoGenomics to Buy amid revenue and margin growth
- 02/24/23 Jefferies
- Esperion assumed at Buy from Hold at Jefferies
- 02/03/23 Morgan Stanley
- Esperion upgraded to Equal Weight from Underweight at Morgan Stanley
- 12/07/22 H.C. Wainwright
- H.C. Wainwright bullish on Esperion as CLEAR Outcomes meets primary endpoint
- 08/03/22 Credit Suisse
- Esperion downgraded to Underperform from Neutral at Credit Suisse
- 02/24/23 Canaccord
- Kratos Defense upgraded to Buy at Canaccord on space and drone strength
- 02/24/23 Canaccord
- Kratos Defense upgraded to Buy from Hold at Canaccord
- 11/04/22 Canaccord
- Kratos Defense downgraded to Hold at Canaccord after guidance cut
- 11/04/22 Canaccord
- Kratos Defense downgraded to Hold from Buy at Canaccord
- 02/24/23 UBS
- Vipshop upgraded to Buy at UBS on apparel demand recovery
- 02/24/23 Nomura
- Nomura upgrades Vipshop to Buy on China apparel recovery
- 02/24/23 Nomura
- Vipshop upgraded to Buy from Neutral at Nomura
- 02/24/23 UBS
- Vipshop upgraded to Buy from Neutral at UBS
- 02/24/23 Evercore ISI
- Domino's target lowered, removed from 'Tactical Underperform' list at Evercore
- 02/24/23 BMO Capital
- Domino's Pizza price target lowered to $380 from $430 at BMO Capital
- 02/24/23 Morgan Stanley
- Domino's Pizza price target lowered to $405 from $430 at Morgan Stanley
- 02/24/23 BTIG
- Domino's Pizza price target lowered to $400 from $460 at BTIG
- 02/24/23 JPMorgan
- C4 Therapeutics downgraded to Underweight from Neutral at JPMorgan
- 11/04/22 JPMorgan
- C4 Therapeutics downgraded to Neutral on catalyst outlook at JPMorgan
- 11/04/22 JPMorgan
- C4 Therapeutics downgraded to Neutral from Overweight at JPMorgan
- 10/11/22 Morgan Stanley
- C4 Therapeutics initiated with an Underweight at Morgan Stanley
- 02/24/23 SVB Securities
- Nektar price target lowered to $3 from $5 at SVB Securities
- 02/24/23 Jefferies
- Nektar downgraded to Underperform from Hold at Jefferies
- 11/29/22 Guggenheim
- Guggenheim starts Medicenna Therapeutics with a Buy on MDNA11 potential
- 08/08/22 JPMorgan
- Nektar downgraded to Underweight from Neutral at JPMorgan
- 02/22/23 BMO Capital
- AbCellera price target lowered to $32 from $40 at BMO Capital
- 02/15/23 Societe Generale
- Societe Generale downgrades Eli Lilly to Sell, says 'time to take profits'
- 02/15/23 Societe Generale
- Eli Lilly downgraded to Sell from Hold at Societe Generale
- $143.20 /
-4.435 (-3.00%) - 02/24/23 SVB Securities
- SVB downgrades Moderna to Underperform as COVID boom reverses
- 02/24/23 SVB Securities
- Moderna downgraded to Underperform from Market Perform at SVB Securities
- 02/23/23 Morgan Stanley
- Moderna price target lowered to $185 from $205 at Morgan Stanley
- 02/23/23 BofA
- Investors could become cautious in near-term on Moderna, says BofA
- 11/10/22 H.C. Wainwright
- Arbutus Biopharma price target lowered to $6 from $7.50 at H.C. Wainwright
- 03/14/22 H.C. Wainwright
- Arbutus Biopharma price target raised to $8.50 from $8 at H.C. Wainwright
- 03/04/22 Chardan
- Arbutus Biopharma price target raised to $6 from $5.50 at Chardan
- 02/24/23 Canaccord
- Alnylam price target lowered to $291 from $310 at Canaccord
- 02/24/23 Citi
- Alnylam price target lowered to $265 from $270 at Citi
- 02/21/23 EF Hutton
- Alnylam initiated with a Buy at EF Hutton
- 02/24/23 Canaccord
- Yeti price target lowered to $54 from $58 at Canaccord
- 02/24/23 Raymond James
- Yeti price target lowered to $45 from $55 at Raymond James
- 02/24/23 Baird
- Yeti price target lowered to $55 from $60 at Baird
- 02/24/23 Goldman Sachs
- Yeti downgraded to Neutral from Buy at Goldman Sachs
- 02/24/23 Barclays
- MGM Resorts initiated with an Overweight at Barclays
- 02/09/23 Deutsche Bank
- MGM Resorts price target raised to $53 from $49 at Deutsche Bank
- 02/09/23 Truist
- MGM Resorts price target raised to $54 from $50 at Truist
- 02/09/23 JMP Securities
- MGM Resorts price target raised to $60 from $56 at JMP Securities
- 02/24/23 Goldman Sachs
- Erasca initiated with a Buy at Goldman Sachs
- 02/03/23 Morgan Stanley
- Erasca upgraded to Overweight from Equal Weight at Morgan Stanley
- 02/24/23 Scotiabank
- HashiCorp initiated with a Sector Perform, $34 target at Scotiabank
- 02/23/23 Scotiabank
- HashiCorp initiated with a Sector Perform at Scotiabank
- 02/13/23 MoffettNathanson
- HashiCorp initiated with an Outperform at MoffettNathanson
- 01/09/23 FBN Securities
- HashiCorp initiated with an Outperform at FBN Securities
- 02/24/23 Janney Montgomery Scott
- ChargePoint initiated with a Buy at Janney Montgomery Scott
- 01/26/23 JPMorgan
- ChargePoint price target lowered to $16 from $18 at JPMorgan
- 12/22/22 Piper Sandler
- ChargePoint price target lowered to $13 from $16 at Piper Sandler
- 12/05/22 DA Davidson
- ChargePoint price target lowered to $18 from $20 at DA Davidson
- 02/24/23 Craig-Hallum
- Craig-Hallum initiates 'exciting growth story' Bowlero with a Buy
- 02/24/23 Craig-Hallum
- Bowlero initiated with a Buy at Craig-Hallum
- 10/03/22 Oppenheimer
- Bowlero initiated with an Outperform at Oppenheimer
- 09/16/22 JPMorgan
- Bowlero price target raised to $18 from $17 at JPMorgan
- 02/23/23
- Yeti sees FY23 adjusted EPS $2.12-$2.23, consensus $2.82
- 02/23/23
- Yeti reports Q4 adjusted EPS 78c, consensus 79c
- 02/23/23
- Vipshop sees Q1 revenue flat to up 5%, consensus $3.6B
- 02/23/23
- Vipshop reports Q4 EPS 53c, consensus 47c
- 11/22/22
- Vipshop sees Q4 revenue RMB 30.7B-RMB 32.4B
- 11/22/22
- Vipshop reports Q3 EPS 36c, consensus 24c
- 02/23/23
- Block reports Q4 EPS 22c, consensus 30c
- 02/23/23
- Notable companies reporting after market close
- 11/03/22
- Block reports Q3 adjusted EPS 42c, consensus 23c
- 11/03/22
- Notable companies reporting after market close
- 11/03/22
- Nektar reports Q3 EPS (31c), consensus (45c)
- 02/23/23
- NeoGenomics sees 2023 revenue $545M-$555M, consensus $545.08M
- 02/23/23
- NeoGenomics reports Q4 adjusted EPS (6c), consensus (16c)
- 11/08/22
- NeoGenomics Q3 adjusted EPS (14c), consensus (21c)
- $143.20 /
-4.435 (-3.00%) - 02/23/23
- Moderna reports Q4 EPS $3.61, consensus $4.67
- 11/03/22
- Moderna reports Q3 EPS $2.53, consensus $3.29
- 02/08/23
- MGM Resorts reports Q4 adjusted EPS ($1.53), consensus ($1.36)
- 02/08/23
- Notable companies reporting after market close
- 11/02/22
- MGM Resorts reports Q3 adjusted EPS ($1.39), consensus 23c
- 11/02/22
- Notable companies reporting after market close
- 02/02/23
- Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30
- 02/02/23
- Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78
- 02/01/23
- Notable companies reporting before tomorrow's open
- 02/23/23
- Kratos Defense reports Q4 EPS 8c, consensus 8c
- 11/04/22
- Kratos Defense lowers FY22 revenue view to $880M-$900M from $890M-$930M
- 11/04/22
- Kratos Defense sees Q4 revenue $231M-251M, consensus $259.1M
- 11/03/22
- Kratos Defense reports Q3 EPS 8c, consensus 7c
- 12/07/22
- HashiCorp raises FY23 EPS view to (71c)-(69c) from (97c)-(95c), consensus (96c)
- 12/07/22
- HashiCorp sees Q4 EPS (23c)-(21c), consensus (30c)
- 12/07/22
- HashiCorp reports Q3 EPS (13c), consensus (31c)
- 09/01/22
- HashiCorp sees FY23 EPS (97c)-(95c), consensus ($1.17)
- 02/21/23
- Esperion reports Q4 EPS (76c), consensus (84c)
- 01/08/23
- Esperion reports preliminary Q4 revenue $14.4M-$15.1M, consensus $21.07M
- 11/01/22
- Esperion reports Q3 EPS (81c), consensus (92c)
- 11/09/22
- Erasca reports Q3 EPS (29c), consensus (31c)
- 02/23/23
- Domino's Pizza reports Q4 EPS $4.43, consensus $3.95
- 02/22/23
- Notable companies reporting before tomorrow's open
- 10/13/22
- Domino's Pizza reports Q3 EPS $2.79, consensus $2.97
- 12/01/22
- ChargePoint narrows FY23 revenue view to $475M-$485M from $450M-$500M
- 12/01/22
- ChargePoint sees Q4 revenue $160M-$170M, consensus $160.91M
- 12/01/22
- ChargePoint reports Q3 EPS (25c), consensus (19c)
- 12/01/22
- Notable companies reporting after market close
- 02/23/23
- C4 Therapeutics reports 2022 EPS ($2.62), consensus ($2.57)
- 11/03/22
- C4 Therapeutics reports Q3 EPS (65c), consensus (67c)
- 02/15/23
- Bowlero reports Q2 adjusted EBITDA $97M, up 45.2% y/y
- 11/16/22
- Bowlero reports Q1 adjusted EBITDA $65.3M, up 11% y/y
- 09/15/22
- Bowlero reports Q4 adjusted EBITDA $82.4M, up 94.8% y/y
- 02/23/23
- Alnylam sees FY23 revenue $1.2B-$1.285B, consensus $1.48B
- 02/23/23
- Alnylam reports Q4 EPS ($1.39), consensus ($1.90)
- 10/27/22
- Alnylam reports Q3 EPS ($1.58), consensus ($1.77)
- 11/09/22
- Arbutus Biopharma reports Q3 EPS (12c), consensus (13c)
|
Recommendations
|
SVB Securities analyst… SVB Securities analyst Daina Graybosch lowered the firm's price target on Nektar to $3 from $5 and keeps a Market Perform rating on the shares following topline Phase 2 ISLAND-SLE results for rezpegaldesleukin in patients with moderate-to-severe systemic erythematosus lupus. The analyst said that although rezpeg demonstrated some encouraging signals of clinical activity in SLE, they understand Lilly's (LLY) decision to discontinue efforts based on "inconsistent clinical outcomes and a narrow therapeutic window weighed against a justifiably high internal go/no-go bar in SLE." SVB sees "considerable uncertainty going forward for rezpeg," and in the next months, sees "potential upside, downside, and muddy scenarios for Nektar." ShowHide Related Items >><< - 02/23/23
- Nektar down 31% afterhours after update on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading resumes
- 02/23/23
- Nektar reports Phase 2 data on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading halted, news pending
- 02/24/23 Jefferies
- Nektar downgraded to Underperform from Hold at Jefferies
- 11/29/22 Guggenheim
- Guggenheim starts Medicenna Therapeutics with a Buy on MDNA11 potential
- 08/08/22 JPMorgan
- Nektar downgraded to Underweight from Neutral at JPMorgan
- 05/31/22 Jefferies
- Nektar assumed with a Hold at Jefferies
- 11/03/22
- Nektar reports Q3 EPS (31c), consensus (45c)
- 02/23/23
- Fly Intel: After-Hours Movers
|
Downgrade
|
Jefferies analyst Roger… Jefferies analyst Roger Song downgraded Nektar Therapeutics (NKTR) to Underperform from Hold with a price target of $1.50, down from $3.20. The Phase 2 of rezpegaldesleukin in systemic lupus erythematosus did not meet primary endpoint or high efficacy hurdle set by partner Eli Lilly (LLY), the analyst tells investors in a research note. While Nektar does not see readthrough to other indications including Alzheimer's given different diseases, the firm sees lower confidence and risk of stopping the entire rezpegaldesleukin program. It downgraded the shares to Underperform citing limited near-term upside events. ShowHide Related Items >><< - 02/23/23
- Nektar down 31% afterhours after update on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading resumes
- 02/23/23
- Nektar reports Phase 2 data on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading halted, news pending
- 02/13/23
- Eli Lilly to supply API for insulin at reduced price to IABL
- 01/27/23
- Eli Lilly says FDA approves Jaypirca
- 01/24/23
- Eli Lilly trading resumes
- 11/29/22 Guggenheim
- Guggenheim starts Medicenna Therapeutics with a Buy on MDNA11 potential
- 08/08/22 JPMorgan
- Nektar downgraded to Underweight from Neutral at JPMorgan
- 05/31/22 Jefferies
- Nektar assumed with a Hold at Jefferies
- 04/20/22 Oppenheimer
- Nektar downgraded to Perform from Outperform at Oppenheimer
- 02/22/23 BMO Capital
- AbCellera price target lowered to $32 from $40 at BMO Capital
- 02/15/23 Societe Generale
- Societe Generale downgrades Eli Lilly to Sell, says 'time to take profits'
- 02/15/23 Societe Generale
- Eli Lilly downgraded to Sell from Hold at Societe Generale
- 02/03/23 Morgan Stanley
- Eli Lilly price target raised to $455 from $440 at Morgan Stanley
- 11/03/22
- Nektar reports Q3 EPS (31c), consensus (45c)
- 02/02/23
- Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30
- 02/02/23
- Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78
- 02/01/23
- Notable companies reporting before tomorrow's open
- 12/19/22
- Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 10/11/22
- New quality issues found at Eli Lilly drug plant, Reuters reports
- 02/23/23
- Fly Intel: After-Hours Movers
- 02/02/23
- What You Missed On Wall Street On Thursday
- 02/02/23
- What You Missed On Wall Street This Morning
- 02/02/23
- Fly Intel: Pre-market Movers
- 01/23/23
- Biotech Alert: Searches spiking for these stocks today
- 11/01/22
- Unusually active option classes on open November 1st
- 10/03/22
- Eli Lilly And Co put volume heavy and directionally bearish
- 09/28/22
- Early notable gainers among liquid option names on September 28th
- 09/28/22
- Unusually active option classes on open September 28th
|
On The Fly
|
Check out this evening's… ShowHide Related Items >><< - 02/23/23
- Verra Mobility to replace Columbia Banking in S&P 600 at open on 3/1
- 12/16/22
- Verra Mobility names Jon Keyser as Chief Legal Officer
- 12/06/22
- Verra Mobility, Car IQ announce partnership
- 11/21/22
- Verra Mobility announces $100M share repurchase plan, debt management initiative
- 02/22/23
- Vicor announces global distribution agreement with Avnet
- 12/21/22
- Boeing launches O3b mPOWER satellite, milestone for Vicor
- 11/03/22
- Vicor announces U.S. Senator Market toured its ChiP fab
- 10/12/22
- Vicor launches 'Powering Innovation' podcast
- 02/23/23
- Block sees FY23 adjusted EBITEA at $1.3B vs. $991M in FY22
- 02/23/23
- Block sees combined company gross profit in January-February up 25%
- 02/23/23
- Block reports Q4 cash app gross profit $848M vs. $518M last year
- 02/23/23
- Block reports Q4 gross payment volume $48.6B vs. $42.6B last year
- 12/06/22
- Sweetgreen COO Chris Carr to depart, Stephanie Traut to oversee operations
- 11/30/22
- Rubicon Technologies signs extended waste diversion agreement with Sweetgreen
- 11/14/22
- Sweetgreen opens first order ahead drive-up format, 'sweetlane'
- 09/13/22
- Sweetgreen to open first locations in Indiana, Minnesota
- 01/19/23
- Avita Medical announces COO McGee leaving, CFO Holder to depart
- 12/19/22
- Avita Medical submits FDA PMA application to expand indication of Vitiligo
- 12/12/22
- Avita Medical submits PMA supplement application for RECELL System
- 11/09/22
- Avita Medical updates results from clinical trial of RECELL System
- $297.89 /
+10.42 (+3.62%) - 02/14/23
- Insulet acquires assets of Automated Glucose Control for $25M
- 02/13/23
- Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M
- 12/14/22
- Insulet COO Alpuche to retire
- 11/14/22
- Insulet issues nationwide voluntary device correction for Omnipod 5 controller
OPEN Opendoor Technologies - 02/14/23
- Opendoor Technologies announces inducement grants under Nasdaq listing rule
- 01/05/23
- Redfin: Pending U.S. home sales dropped 32% y/y during four weeks ending Jan1
- 12/01/22
- Opendoor names CFO Carrie Wheeler CEO
- 11/14/22
- Opendoor Technologies director sells $8.9M in common stock
- 02/23/23
- Oceaneering sees FY23 adjusted EBITDA of $260M-$310M vs. $232.6M last year
- 02/23/23
- Oceaneering sees Q1 adjusted EBITDA at $40M-$50M
- 02/15/23
- Oceaneering's OMR business awarded significant contracts
- 10/27/22
- Oceaneering rises 19.0%
- 02/23/23
- Nektar down 31% afterhours after update on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading resumes
- 02/23/23
- Nektar reports Phase 2 data on rezpegaldesleukin in lupus
- 02/23/23
- Nektar trading halted, news pending
- 10/31/22
- Mister Car Wash names Luke Hartke as VP of M&A
- 10/03/22
- Mister Car Wash to replace ExlService in S&P 600 at open on 10/3
- 09/26/22
- Mister Car Wash rises 11.0%
- 09/26/22
- Mister Car Wash rises 11.2%
- 01/20/23
- Live Nation, KIDZ BOP announce 2023 KIDZ BOP Never Stop Tour
- 01/09/23
- Live Nation down 1% after launching $850M convertible senior notes offering
- 12/01/22
- Live Nation director Iovine acquires 13,740 common shares
- 11/23/22
- Congress to hold hearing on Ticketmaster issue after Taylor Swift mess
- 11/09/22
- Open Lending appoints Fillarini as CHRO, Nguyen as CIO
- 10/07/22
- Open Lending announces Flynn to retire as CEO, Jezek to succeed
- 01/19/23
- CS Disco to reduce workforce by 9%
- 11/11/22
- CS Disco rises 18.4%
- 09/26/22
- CS Disco falls -10.6%
- 09/26/22
- CS Disco falls -8.1%
- 02/23/23
- Intuit names Sandeep Singh Aujla as new CFO
- 02/08/23
- Asure teams with Intuit's TurboTax to aid small businesses with taxes, hiring
- 01/05/23
- Nordstrom appoints Atticus Tysen to Board of Directors
- 12/06/22
- AvidXchange announces invoice-to-pay API integration with Intuit QuickBooks
- 02/23/23
- Farfetch CFO Jordan to step down by end of 2023
- 01/18/23
- Farfetch announces changes to leadership team
- 12/29/22
- Farfetch rises 11.7%
- 12/01/22
- Farfetch falls -20.2%
- 02/23/23
- Floor & Decor reports Q4 SSS up 2.5%
- 02/14/23
- Lone Pine exited PayPal, initiated AMD position during Q4
- 11/29/22
- Floor & Decor names Bryan Langley CFO
- 11/03/22
- Floor & Decor reports Q3 SSS up 11.6%
- 02/23/23
- Expensify affirms long-term guidance
- 02/23/23
- Expensify reports Q4 EPS (4c), consensus 7c
- 01/10/23
- Expensify announces it purchased additional 81,999 shares of its stock
- 11/29/22
- Expensify announces 599,080 shares repurchased in open market
- 02/23/23
- Carvana sees sequential reduction in retail units sold in Q1 vs Q4
- 02/08/23
- Carvana trading resumes
- 02/08/23
- Carvana trading halted, volatility trading pause
- 02/02/23
- Carvana rises 28.6%
- 02/23/23
- Columbia Banking to replace Umpqua Holdings in S&P 400 at open on 3/1
- 01/09/23
- Columbia Banking and Umpqua announce FDIC approval of combination
- 11/07/22
- Columbia Banking agrees to sell seven branches to 1st Security
- 02/23/23
- Beyond Meat 'encouraged' by 14% improvement in margin expansion
- 02/23/23
- Beyond Meat up 15% after reporting Q4 earnings results
- 01/03/23
- Beyond Meat says 'Beyond Steak' now available at select Costco locations
- 12/29/22
- Beyond Meat rises after McDonald's UK&I announces 'Double McPlant'
- $2,428.00 /
+3.23 (+0.13%) - 02/23/23
- Booking announces $20B share repurchase authorization
- 02/23/23
- Booking Holdings CEO says 'proud of our company's performance' in 2022
- 02/13/23
- Soros Fund buys Horizon Therapeutics, exits BNY Mellon in Q4
- $221.28 /
+4.795 (+2.21%) - 02/21/23
- Procore announces Sarah Hodges as CMO, effective immediately
- 11/22/22
- Autodesk sees some exogenous revenue headwinds 'out of the gate' in FY24
- 11/22/22
- Autodesk falls 7% to $194.50 after Q3 results, FY23 guidance
- 10/12/22 Piper Sandler
- CMS proposal a positive for Med Tech sector, says Piper Sandler
- 09/12/22 Piper Sandler
- Avita Medical data for stable vitiligo treatment excellent, says Piper Sandler
- 03/01/22 BTIG
- Avita Medical price target lowered to $21 from $37 at BTIG
- 03/01/22 Piper Sandler
- Avita Medical price target lowered to $15 from $23 at Piper Sandler
- 02/17/23 Piper Sandler
- Beyond Meat will issue shares to maintain liquidity, says Piper Sandler
- 12/09/22 Argus
- Beyond Meat downgraded to Sell at Argus on declining demand, competition
- 11/28/22 Barclays
- Beyond Meat downgraded to Underweight from Equal Weight at Barclays
- 11/23/22 Goldman Sachs
- Beyond Meat price target lowered to $5 from $14 at Goldman Sachs
- 02/22/23 KeyBanc
- Block price target raised to $100 from $90 at KeyBanc
- 02/03/23 Credit Suisse
- Lightspeed downgraded to Neutral from Outperform at Credit Suisse
- 01/25/23 Oppenheimer
- Block downgraded to Perform from Outperform at Oppenheimer
- 01/23/23 Barclays
- Block price target raised to $103 from $100 at Barclays
- 01/30/23 KeyBanc
- KeyBanc keeps Overweight on Farfetch, lowers price target to $11
- 12/15/22 Oppenheimer
- Farfetch price target lowered to $7 from $14 at Oppenheimer
- 12/05/22 TD Cowen
- Farfetch price target lowered to $8 from $11 at Cowen
- 12/02/22 Wells Fargo
- Farfetch price target lowered to $18 from $25 at Wells Fargo
- 02/17/23 Evercore ISI
- Floor & Decor added to 'Tactical Underperform' list at Evercore ISI
- 02/16/23 Telsey Advisory
- Floor & Decor downgraded to Market Perform from Outperform at Telsey Advisory
- 02/15/23 Piper Sandler
- Floor & Decor price target raised to $86 from $66 at Piper Sandler
- 02/15/23 Citi
- Floor & Decor price target raised to $115 from $90 at Citi
- $297.89 /
+10.42 (+3.62%) - 02/22/23 Oppenheimer
- DexCom selloff on Apple article should be bought, says Oppenheimer
- 01/26/23 Wolfe Research
- Insulet initiated with a Peer Perform at Wolfe Research
- 01/04/23 Barclays
- Insulet price target raised to $245 from $238 at Barclays
- 12/12/22 Baird
- Insulet price target raised to $340 from $315 at Baird
- 10/21/22 Stifel
- Mister Car Wash downgraded on lack of earnings visibility at Stifel
- 10/21/22 Stifel
- Mister Car Wash downgraded to Hold from Buy at Stifel
- 10/03/22 MKM Partners
- MKM starts Mister Car Wash at Neutral amid 'number of challenges'
- 10/03/22 MKM Partners
- Mister Car Wash initiated with a Neutral at MKM Partners
- 12/08/22 Jefferies
- Live Nation price target lowered to $92 from $120 at Jefferies
- 11/30/22 Morgan Stanley
- Live Nation price target lowered to $80 from $95 at Morgan Stanley
- 11/28/22 Citi
- Live Nation upgraded to Buy from Neutral at Citi
- 11/22/22 Redburn
- Redburn starts Live Nation with a Neutral
- 01/10/23 Exane BNP Paribas
- Intuit downgraded to Underperform from Neutral at Exane BNP Paribas
- 01/04/23 KeyBanc
- Intuit price target raised to $425 from $400 at KeyBanc
- 12/01/22 Argus
- Intuit fundamentals remains sound, says Argus
- 12/01/22 Citi
- Intuit price target lowered to $462 from $498 at Citi
- 07/20/22 Deutsche Bank
- Verra Mobility price target raised to $19 from $18 at Deutsche Bank
- 07/13/22 William Blair
- Verra Mobility selloff a buying opportunity, says William Blair
- 07/13/22 Baird
- Verra Mobility downgraded to Neutral from Outperform at Baird
- 06/09/22 Baird
- Verra Mobility price target lowered to $18 from $20 at Baird
- 01/12/23 Citi
- CS Disco downgraded to Neutral from Buy at Citi
- 01/04/23 BofA
- BofA cuts CS Disco to Underperform on uncertain demand for high revenue product
- 01/04/23 Canaccord
- Canaccord upgrades 'too darn cheap' CS Disco to Buy
- 01/04/23 BofA
- CS Disco downgraded to Underperform from Neutral at BofA
- 02/21/23 Canaccord
- Open Lending price target lowered to $20 from $30 at Canaccord
- 11/07/22 Deutsche Bank
- Open Lending price target lowered to $10 from $16 at Deutsche Bank
- 11/01/22 DA Davidson
- Open Lending price target lowered to $22 from $26 at DA Davidson
- 10/07/22 Stephens
- Open Lending 2022 guidance reiteration a positive, says Stephens
- 01/17/23 Raymond James
- Upland Software downgraded to Market Perform from Outperform at Raymond James
- 11/21/22 Credit Suisse
- Upland Software initiated with a Neutral at Credit Suisse
- 11/07/22 Truist
- Upland Software price target lowered to $12 from $20 at Truist
- 08/04/22 Craig-Hallum
- Upland Software price target lowered to $13 from $22 at Craig-Hallum
- 01/19/23 Benchmark
- Oceaneering initiated with a Buy at Benchmark
- 10/19/22 Citi
- Oceaneering price target lowered to $16 from $20 at Citi
- 10/07/22 Piper Sandler
- Oceaneering assumed with a Neutral at Piper Sandler
- 10/06/22 Barclays
- Barclays downgrades Oceaneering on lack of 'earnings torque'
- 02/07/23 TD Cowen
- Cowen downgrades Sweetgreen on sales, profitability risks
- 02/07/23 TD Cowen
- Sweetgreen downgraded to Market Perform from Outperform at Cowen
- 01/18/23 JPMorgan
- Sweetgreen price target lowered to $13 from $18 at JPMorgan
- 01/17/23 Morgan Stanley
- Sweetgreen downgraded to Equal Weight from Overweight at Morgan Stanley
- 10/26/22 CJS Securities
- Vicor upgraded to Outperform from Market Perform at CJS Securities
- 10/21/22 Craig-Hallum
- Vicor price target lowered to $70 from $100 at Craig-Hallum
- 10/21/22 Craig-Hallum
- Vicor price target lowered to $70 from $100 at Craig-Hallum
- 10/11/22 Needham
- Vicor price target lowered to $65 from $75 at Needham
OPEN Opendoor Technologies - 02/14/23 Citi
- Opendoor Technologies price target raised to $2 from $1.50 at Citi
- 12/29/22 BTIG
- Opendoor Technologies valuation remains attractive, says BTIG
- 12/21/22 Truist
- Opendoor Technologies cut to Hold at Truist on high inventory, price correction
- 12/21/22 Truist
- Opendoor Technologies downgraded to Hold from Buy at Truist
- 02/21/23 DA Davidson
- Carvana price target raised to $7 from $5 at DA Davidson
- 02/16/23 Piper Sandler
- Carvana price target lowered to $21 from $45 at Piper Sandler
- 01/26/23 JMP Securities
- Carvana price target lowered to $15 from $25 at JMP Securities
- 01/17/23 Raymond James
- Carvana poison pill suggests board's defensive stance, says Raymond James
- 01/17/23 Morgan Stanley
- Expensify initiated with an Equal Weight at Morgan Stanley
- 12/07/22 Lake Street
- Expensify initiated with a Buy at Lake Street
- 11/11/22 Piper Sandler
- Expensify downgraded to Neutral from Overweight at Piper Sandler
- 10/21/22 Citi
- Expensify price target lowered to $20 from $25 at Citi
- $221.28 /
+4.795 (+2.21%) - 02/21/23 Stifel
- Autodesk price target raised to $245 from $220 at Stifel
- 02/21/23 Baird
- Autodesk price target raised to $255 from $244 at Baird
- 02/17/23 RBC Capital
- Autodesk price target raised to $250 from $225 at RBC Capital
- 02/15/23 Mizuho
- Autodesk price target raised to $220 from $200 at Mizuho
- $2,428.00 /
+3.23 (+0.13%) - 02/23/23 Oppenheimer
- Booking Holdings price target raised to $2,850 from $2,550 at Oppenheimer
- 02/13/23 Deutsche Bank
- Booking Holdings price target raised to $2,910 from $2,370 at Deutsche Bank
- 01/25/23 BofA
- Expedia price target raised to $143 from $138 at BofA
- 01/25/23 BofA
- Booking downgraded to Neutral at BofA after outperformance
- 11/29/22 Guggenheim
- Guggenheim starts Medicenna Therapeutics with a Buy on MDNA11 potential
- 08/08/22 JPMorgan
- Nektar downgraded to Underweight from Neutral at JPMorgan
- 05/31/22 Jefferies
- Nektar assumed with a Hold at Jefferies
- 04/20/22 Oppenheimer
- Nektar downgraded to Perform from Outperform at Oppenheimer
- 01/25/23 RBC Capital
- Columbia Banking price target lowered to $33 from $37 at RBC Capital
- 05/02/22 Piper Sandler
- Columbia Banking price target lowered to $31 from $35 at Piper Sandler
- 11/02/22
- Verra Mobility now sees 2022 revenue at higher end of $720M-$740M
- 11/02/22
- Verra Mobility reports Q3 adjusted EPS 27c, consensus 27c
- 02/23/23
- Vicor reports Q4 EPS 18c, consensus 21c
- 10/25/22
- Vicor reports Q3 EPS 18c, consensus 21c
- 02/23/23
- Upland Software sees FY23 revenue $288M-$312M, consensus $311.74M
- 02/23/23
- Upland Software sees Q1 revenue $72M-$78M, consensus $76.85M
- 02/23/23
- Upland Software reports Q4 adjusted EPS 37c, consensus 39c
- 11/03/22
- Upland Software sees FY22 revenue $312.6M-$329M, consensus $316.1M
- 02/23/23
- Block reports Q4 EPS 22c, consensus 30c
- 11/03/22
- Block reports Q3 adjusted EPS 42c, consensus 23c
- 11/03/22
- Notable companies reporting after market close
- 02/23/23
- Sweetgreen sees FY23 revenue $575M-$595M, consensus $628.8M
- 02/23/23
- Sweetgreen sees Q1 revenue $124M-$127M, consensus $124.7M
- 02/23/23
- Sweetgreen reports Q4 EPS (44c), consensus (35c)
- 11/08/22
- Sweetgreen sees FY22 revenue 'at lower end of slightly below' prior outlook
- 02/23/23
- Avita Medical reports Q4 EPS (21c), consensus (29c)
- $297.89 /
+10.42 (+3.62%) - 02/23/23
- Insulet sees FY23 revenue growth 14%-19%, consensus $1.47B
- 02/23/23
- Insulet sees Q1 revenue growth 11%-14%, consensus $333.86M
- 02/23/23
- Insulet reports Q4 adjusted EPS 55c, consensus 21c
- 11/03/22
- Insulet raises FY22 revenue growth view to 18%-19% from 14%-17%
OPEN Opendoor Technologies - 02/23/23
- Opendoor Technologies sees Q1 revenue $2.45B-$2.65B, consensus $2.56B
- 02/23/23
- Opendoor Technologies reports Q4 EPS (63c), consensus (73c)
- 11/03/22
- Opendoor Technologies sees Q4 revenue $2.3B-$2.5B, consensus $2.63B
- 02/23/23
- Oceaneering reports Q4 adjusted EPS 6c, consensus 19c
- 10/26/22
- Oceaneering reports Q3 adjusted EPS 23c, consensus 11c
- 11/03/22
- Nektar reports Q3 EPS (31c), consensus (45c)
- 02/23/23
- Mister Car Wash sees FY23 EPS 30c-35c, consensus 38c
- 02/23/23
- Mister Car Wash reports Q4 EPS 8c, consensus 6c
- 11/10/22
- Mister Car Wash narrows FY22 EPS view to 38c-39c from 36c-39c, consensus 38c
- 11/10/22
- Mister Car Wash reports Q3 adjusted EPS 9c, consensus 8c
- 02/23/23
- Live Nation reports Q4 revenue $4.29B, consensus $3.6B
- 11/03/22
- Live Nation reports Q3 EPS $1.39, consensus $1.03
- 02/23/23
- Open Lending sees Q1 revenue $30M-$34M, consensus $38.0M
- 02/23/23
- Open Lending reports Q4 EPS (3c), consensus 10c
- 10/07/22
- Open Lending backs FY22 guidance
- 02/23/23
- CS Disco sees FY23 revenue $135M-$145M, consensus $155.85M
- 02/23/23
- CS Disco sees Q1 revenue $30.5M-$32.5M, consensus $34.81M
- 02/23/23
- CS Disco reports Q4 EPS (32c), consensus (31c)
- 01/19/23
- CS Disco sees FY22 revenue $132M-$136M, consensus $134.15M
- 02/23/23
- Intuit reports Q2 EPS $2.20, consensus $1.44
- 11/29/22
- Intuit sees Q2 adjusted EPS $1.41-$1.45, consensus $2.06
- 11/29/22
- Intuit backs FY23 adjusted EPS view $13.59-$13.89, consensus $13.75
- 02/23/23
- Farfetch sees FY23 adjusted EBITDA margin 1%-3%
- 02/23/23
- Farfetch reports Q4 adjusted EPS (25c), consensus (47c)
- 11/17/22
- Farfetch reports Q3 adjusted EPS (24c), consensus (28c)
- 02/23/23
- Floor & Decor sees FY23 EPS $2.55-$2.85, consensus $2.85
- 02/23/23
- Floor & Decor reports Q4 EPS 64c, consensus 57c
- 11/03/22
- Floor & Decor narrows FY22 EPS view lower to $2.65-$2.75, consensus $2.71
- 11/03/22
- Floor & Decor reports Q3 EPS 70c, consensus 65c
- 11/10/22
- Expensify reports Q3 EPS (10c), consensus 8c
- 02/23/23
- Carvana reports Q4 EPS ($7.61) vs ($1.02) last year
- 11/03/22
- Carvana sees sequential reduction in retail units sold in Q4
- 11/03/22
- Carvana reports Q3 EPS ($2.67), consensus ($1.94)
- 01/24/23
- Columbia Banking reports Q4 EPS 88c, consensus 89c
- 10/20/22
- Columbia Banking reports Q3 EPS 83c, consensus 74c
- 02/23/23
- Beyond Meat sees FY23 revenue $375M-$415M, consensus $394.2M
- 02/23/23
- Beyond Meat reports Q4 EPS ($1.05), consensus ($1.18)
- 02/23/23
- Notable companies reporting after market close
- 11/09/22
- Beyond Meat cuts FY22 revenue view to $400M-$425M from $470M-$520M
- $2,428.00 /
+3.23 (+0.13%) - 02/23/23
- Booking Holdings reports Q4 adjusted EPS $24.74, consensus $22.24
- 11/02/22
- Booking Holdings reports Q3 adjusted EPS $53.03, consensus $49.85
- 11/02/22
- Notable companies reporting after market close
- $221.28 /
+4.795 (+2.21%) - 02/23/23
- Autodesk sees FY24 non-GAAP EPS $6.98-$7.32, consensus $7.31
- 02/23/23
- Autodesk reports 4Q non-GAAP EPS $1.86, consensus $1.81
- 11/22/22
- Autodesk sees FY23 non-GAAP EPS $6.56-$6.62, consensus $6.62
|